We support the development of novel medicines that address significant unmet medical needs.
As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making.
Investment strategy and approach
Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval.
Therapeutic area focus
All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story.
Medical devices, digital health and diagnostics companies are out of scope.
Stage of company
We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing.
Geographic footprint
We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem.
Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind.
Our Core Values
DECENT
- We show respect at all times
- We act with integrity and always aim to do the right thing
- Being reasonable builds long-term relationships
DEDICATED
- We work hard to deliver results for patients, our companies and our LPs
- We are highly professional
- We love what we do
CONFIDENT
- Our combined experience is extensive – we have been there before
- We trust our capabilities
- We are supported by a strong and extensive network
HUMBLE
- We know our limitations
- We know when to listen and when to ask questions
- We are responsible stewards of our LP’s capital